HONG KONG, Nov 26, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab”, or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, was invited to attend the inaugural Asia Summit On Global Health (“ASGH”), jointly organized by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC) yesterday, Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, joined the panel discussion on the topic of “What’s Next for Healthcare Innovation and Investment”.
Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of the Company (second right)
With the theme of “Shaping a Resilient and Sustainable Future”, the Inaugural ASGH was held at the Convention Hall of Hong Kong Convention and Exhibition Centre and synchronized online. At the panel discussion with the topic of “What’s Next for Healthcare Innovation and Investment”, Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of the Company, was one of the guest speakers.
Regarding the development of biotechnology and healthcare ecosystem in Hong Kong in recent years, Dr. Shui On LEUNG said that in stead of being a standalone ecosystem, Hong Kong has to merge with either mainland China or other part of the world, and Hong Kong can play the role as a phase I clinical trial center and a trial site. He said that the ecosystem depends on scientific innovation and government involvement. Doing innovative research in Hong Kong enjoys advantages such as legal protection and patenting system, which will facilitate the companies to get licensed with other collaborators. He pointed out that Chapter 18A of the Listing Rules and Guidelines reflects the value of the biotechnology industry, improves market liquidity, and encourages more investment into the biotechnology system.
More than 70 senior government officials, investors, influential business leaders, financial and professional service providers as well as renowned academia from related sectors worldwide were invited to attend the summit to exchange insights and explore business opportunities and partnership. Exhibitions, project pitching and business networking sessions were also be staged to facilitate business negotiation and investment partnerships.
Dr. Shui On LEUNG said, “It is a great honour to attend the Inaugural ASGH on behalf of the Company. Through the communication and sharing with stakeholders including healthcare and technology experts, research and business leader, start-ups, investors and government decision-maker on the summit, the overall development of the ecosystem for the healthcare and biotechnology sectors will be benefited. SM03, the flagship product of the Company, completed the enrolment for Phase 3 clinical trial in this year and expected to readout data next year, indicating that SM03 will soon be commercialized. For business development, we have entered into our first license agreement in September this year. To enhance our R&D and product development capabilities, new plant of over 32,000 liters production capacity of our Suzhou campus is under construction. In the future, the Company will be dedicated to discovering and developing novel drug targets and exploring treatments for immunological diseases, further expanding our product pipeline to fight for patients’ well-being. We will also continue to actively looking for opportunities of collaboration and partnership, consolidate the capital market position of the Company as well as contribute to human healthcare and the biotechnology industry of Hong Kong.”
About SinoMab BioScience Limited
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgar, non-Hodgkin’s lymphoma, asthma, and other diseases with major unmet clinical needs.
Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)